$GLSI
Greenwich LifeSciences, Inc.

2023 Q3 Form 10-Q Financial Statement

#000149315223029605 Filed on August 21, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $340.0K $368.3K $140.1K
YoY Change -48.45% 162.93% -28.87%
% of Gross Profit
Research & Development $2.158M $1.380M $633.3K
YoY Change 25.22% 117.86% 13.78%
% of Gross Profit
Depreciation & Amortization $0.00 $910.00 $910.00
YoY Change -100.0% 0.0% -49.72%
% of Gross Profit
Operating Expenses $2.503M $1.748M $773.3K
YoY Change 5.03% 126.02% 2.64%
Operating Profit -$2.503M -$1.748M -$773.3K
YoY Change 5.03% 126.02% 2.64%
Interest Expense $110.0K $119.5K $27.23K
YoY Change 71.77% 338.67% 635.95%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.390M -$1.628M -$746.1K
YoY Change 3.06% 118.26% -0.49%
Income Tax
% Of Pretax Income
Net Earnings -$2.392M -$1.628M -$746.1K
YoY Change 3.14% 118.26% -0.49%
Net Earnings / Revenue
Basic Earnings Per Share -$0.19 -$0.13 -$0.06
Diluted Earnings Per Share -$0.19 -$0.13 -$57.73K
COMMON SHARES
Basic Shares Outstanding 12.85M shares 12.85M shares
Diluted Shares Outstanding 12.85M shares 12.85M shares 12.92M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.140M $10.94M $17.19M
YoY Change -41.55% -36.33% -42.32%
Cash & Equivalents $9.144M $10.94M $17.19M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $9.140M $10.94M $17.19M
YoY Change -41.55% -36.33% -42.32%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $9.913K $7.199K $10.81K
YoY Change 0.1% -33.4% -25.04%
TOTAL ASSETS
Total Short-Term Assets $9.140M $10.94M $17.19M
Total Long-Term Assets $9.913K $7.199K $10.81K
Total Assets $9.150M $10.95M $17.20M
YoY Change -41.53% -36.32% -42.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $230.0K $300.5K $220.9K
YoY Change 4.14% 36.05% -64.81%
Accrued Expenses $70.00K $1.080K $8.290K
YoY Change 311.04% -86.97% -66.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $297.3K $301.5K $229.1K
YoY Change 24.97% 31.6% -64.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $297.3K $301.5K $229.1K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $297.3K $301.5K $229.1K
YoY Change 24.97% 31.6% -64.89%
SHAREHOLDERS EQUITY
Retained Earnings -$47.62M -$45.23M -$36.36M
YoY Change 23.1% 24.37%
Common Stock $56.47M $55.88M $53.33M
YoY Change 4.4% 4.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.853M $10.65M $16.97M
YoY Change
Total Liabilities & Shareholders Equity $9.150M $10.95M $17.20M
YoY Change -41.53% -36.32% -42.32%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$2.392M -$1.628M -$746.1K
YoY Change 3.14% 118.26% -0.49%
Depreciation, Depletion And Amortization $0.00 $910.00 $910.00
YoY Change -100.0% 0.0% -49.72%
Cash From Operating Activities -$1.800M -$967.0K -$532.7K
YoY Change 16.14% 81.52% -11.6%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 -2.023M
YoY Change -100.0% -71065.26%
NET CHANGE
Cash From Operating Activities -1.800M -967.0K -532.7K
Cash From Investing Activities
Cash From Financing Activities 0.000 0.000 -2.023M
Net Change In Cash -1.800M -967.0K -2.555M
YoY Change 16.14% -62.16% 326.05%
FREE CASH FLOW
Cash From Operating Activities -$1.800M -$967.0K -$532.7K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001799788
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39555
dei Entity Registrant Name
EntityRegistrantName
GREENWICH LIFESCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5473709
dei Entity Address Address Line1
EntityAddressAddressLine1
3992 Bluebonnet Dr.
dei Entity Address Address Line2
EntityAddressAddressLine2
Building 14
dei Entity Address City Or Town
EntityAddressCityOrTown
Stafford
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77477
dei City Area Code
CityAreaCode
(832)
dei Local Phone Number
LocalPhoneNumber
819-3232
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
GLSI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12848165 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10944242 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13468026 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7197 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9003 usd
CY2023Q2 us-gaap Assets
Assets
10951439 usd
CY2022Q4 us-gaap Assets
Assets
13477029 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
300463 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220845 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1083 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
42060 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
301546 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
262905 usd
CY2023Q2 us-gaap Liabilities
Liabilities
301546 usd
CY2022Q4 us-gaap Liabilities
Liabilities
262905 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12848165 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12848165 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12848165 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12848165 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
12848 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12848 usd
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
55863086 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
54674042 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45226041 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41472766 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10649893 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13214124 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10951439 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13477029 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1379567 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
633250 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3207474 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2294071 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
368259 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
140057 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
781434 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
468439 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1747826 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
773307 usd
us-gaap Operating Expenses
OperatingExpenses
3988908 usd
us-gaap Operating Expenses
OperatingExpenses
2762510 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1747826 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-773307 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3988908 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2762510 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
119453 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
27234 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
235633 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
46809 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1628373 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-746073 usd
us-gaap Net Income Loss
NetIncomeLoss
-3753275 usd
us-gaap Net Income Loss
NetIncomeLoss
-2715701 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2023Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12848165 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12848165 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12923434 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12923434 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12848165 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12848165 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
13091915 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13091915 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
26831712 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
165267 usd
CY2022Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
5513711 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1969628 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
19513640 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
224503 usd
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2022505 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-746073 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
16969565 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13214124 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
594522 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2124902 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
11683744 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
11683744 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
594522 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1628373 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10649893 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10649893 usd
us-gaap Net Income Loss
NetIncomeLoss
-3753275 usd
us-gaap Net Income Loss
NetIncomeLoss
-2715701 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
1806 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
1806 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1189044 usd
us-gaap Share Based Compensation
ShareBasedCompensation
389770 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
79618 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-40977 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-156038 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2523784 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2480163 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
7536216 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-7536216 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2523784 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10016379 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13468026 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27204269 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10944242 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17187890 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
2555 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20174 shares
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
220845 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
220845 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
893181 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
908362 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
120 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2009657 usd
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
15181 shares
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
34157 usd
CY2023Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
519828 shares
CY2022Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
519828 shares
CY2023Q2 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
7536216 usd
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0 shares
CY2023Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
49678 usd
CY2023Q2 GLSI Closing Share Price
ClosingSharePrice
9.65

Files In Submission

Name View Source Status
0001493152-23-029605-index-headers.html Edgar Link pending
0001493152-23-029605-index.html Edgar Link pending
0001493152-23-029605.txt Edgar Link pending
0001493152-23-029605-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
glsi-20230630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
glsi-20230630_def.xml Edgar Link unprocessable
glsi-20230630_cal.xml Edgar Link unprocessable
glsi-20230630_lab.xml Edgar Link unprocessable
glsi-20230630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed